Literature DB >> 24685711

Dual opposing roles of adaptive immunity in hypertension.

Noureddine Idris-Khodja1, Muhammad Oneeb Rehman Mian1, Pierre Paradis1, Ernesto L Schiffrin2.   

Abstract

Hypertension involves remodelling and inflammation of the arterial wall. Interactions between vascular and inflammatory cells play a critical role in disease initiation and progression. T effector and regulatory lymphocytes, members of the adaptive immune system, play contrasting roles in hypertension. Signals from the central nervous system and the innate immune system antigen-presenting cells activate T effector lymphocytes and promote their differentiation towards pro-inflammatory T helper (Th) 1 and Th17 phenotypes. Th1 and Th17 effector cells, via production of pro-inflammatory mediators, participate in the low-grade inflammation that leads to blood pressure elevation and end-organ damage. T regulatory lymphocytes, on the other hand, counteract hypertensive effects by suppressing innate and adaptive immune responses. The present review summarizes and discusses the adaptive immune mechanisms that participate in the pathophysiology in hypertension. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Adaptive immunity; Blood pressure; Cytokines; Inflammation; T effector lymphocytes; T regulatory lymphocytes

Mesh:

Substances:

Year:  2014        PMID: 24685711      PMCID: PMC4019914          DOI: 10.1093/eurheartj/ehu119

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  81 in total

1.  Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice.

Authors:  Modar Kassan; Maria Galan; Megan Partyka; Mohamed Trebak; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

2.  Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension.

Authors:  Antony Vinh; Wei Chen; Yelena Blinder; Daiana Weiss; W Robert Taylor; Jörg J Goronzy; Cornelia M Weyand; David G Harrison; Tomasz J Guzik
Journal:  Circulation       Date:  2010-11-29       Impact factor: 29.690

3.  T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats.

Authors:  Carmen De Miguel; Satarupa Das; Hayley Lund; David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-02-10       Impact factor: 3.619

4.  Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension.

Authors:  Jong-Chan Youn; Hee Tae Yu; Beom Jin Lim; Myoung Ju Koh; Jino Lee; Dong-Yeop Chang; Yoon Seok Choi; Sang-Hak Lee; Seok-Min Kang; Yangsoo Jang; Ook Joon Yoo; Eui-Cheol Shin; Sungha Park
Journal:  Hypertension       Date:  2013-05-28       Impact factor: 10.190

5.  Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury.

Authors:  Jing Shao; Masaomi Nangaku; Toshio Miyata; Reiko Inagi; Koei Yamada; Kiyoshi Kurokawa; Toshiro Fujita
Journal:  Hypertension       Date:  2003-05-27       Impact factor: 10.190

6.  Critical role of CXCL16 in hypertensive kidney injury and fibrosis.

Authors:  Yunfeng Xia; Mark L Entman; Yanlin Wang
Journal:  Hypertension       Date:  2013-09-23       Impact factor: 10.190

7.  Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase.

Authors:  Jing Wu; Salim R Thabet; Annet Kirabo; Daniel W Trott; Mohamed A Saleh; Liang Xiao; Meena S Madhur; Wei Chen; David G Harrison
Journal:  Circ Res       Date:  2013-12-17       Impact factor: 17.367

8.  Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice.

Authors:  Lucia Mazzolai; Michel A Duchosal; Martine Korber; Karima Bouzourene; Jean François Aubert; Hiroyuki Hao; Veronique Vallet; Hans-R Brunner; Jürg Nussberger; Giulio Gabbiani; Daniel Hayoz
Journal:  Hypertension       Date:  2004-08-09       Impact factor: 10.190

9.  Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.

Authors:  Brigitte Santner-Nanan; Michael John Peek; Roma Khanam; Luise Richarts; Erhua Zhu; Barbara Fazekas de St Groth; Ralph Nanan
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

10.  Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats.

Authors:  A A Khraibi; R A Norman; D J Dzielak
Journal:  Am J Physiol       Date:  1984-11
View more
  31 in total

Review 1.  Immune Mechanisms in Arterial Hypertension.

Authors:  Ulrich Wenzel; Jan Eric Turner; Christian Krebs; Christian Kurts; David G Harrison; Heimo Ehmke
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

Review 2.  Role of immune cells in hypertension.

Authors:  Antoine Caillon; Pierre Paradis; Ernesto L Schiffrin
Journal:  Br J Pharmacol       Date:  2018-07-20       Impact factor: 8.739

Review 3.  Interactions Between the Immune and the Renin-Angiotensin Systems in Hypertension.

Authors:  Nathan P Rudemiller; Steven D Crowley
Journal:  Hypertension       Date:  2016-06-27       Impact factor: 10.190

4.  Stressed hearts inflame the body (in a good way).

Authors:  Toru Hashimoto; David A Kass
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-21       Impact factor: 11.205

Review 5.  Immunity in arterial hypertension: associations or causalities?

Authors:  Hans-Joachim Anders; Marcus Baumann; Giovanni Tripepi; Francesca Mallamaci
Journal:  Nephrol Dial Transplant       Date:  2015-03-11       Impact factor: 5.992

6.  CXCL1-CXCR2 lead monocytes to the heart of the matter.

Authors:  Pierre Paradis; Ernesto L Schiffrin
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

Review 7.  Influence of Inflammation and Atherosclerosis in Atrial Fibrillation.

Authors:  Rose Mary Ferreira Lisboa da Silva
Journal:  Curr Atheroscler Rep       Date:  2017-01       Impact factor: 5.113

Review 8.  Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?

Authors:  Kenia Pedrosa Nunes; Amanda Almeida de Oliveira; Francesca Elisabeth Mowry; Vinicia Campana Biancardi
Journal:  Br J Pharmacol       Date:  2018-08-09       Impact factor: 8.739

9.  Is microglia the new target for the treatment of resistant hypertension?

Authors:  Eric Lazartigues
Journal:  Hypertension       Date:  2015-06-08       Impact factor: 10.190

Review 10.  Role of mineralocorticoid receptor antagonists in cardiovascular disease.

Authors:  Carlos M Ferrario; Ernesto L Schiffrin
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.